The long-term strategy for AI in drug discovery is a two-step process. First, create an AI platform to design effective drugs. Second, after a dozen or so AI-designed drugs succeed, use that data to convince regulators to trust AI predictions, potentially allowing future drugs to skip steps like animal testing and accelerate trials.

To manage compliance risk in regulated industries, treat AI agents like new employees. Before deployment, the agent must pass the same knowledge assessment a human would take. This quantifies the risk, turning a 'black box' AI into an observable and testable system with a verifiable accuracy score.

In regulated industries like finance, the primary barrier to full AI automation is often regulation, not just user trust. It is the technology provider's responsibility to prove AI's reliability and safety to regulators, much like the industry did to legitimize e-signatures over a decade ago.

AI delivers the most value when applied to mature, well-understood processes, not chaotic ones. Pharma's MLR (Medical, Legal, Regulatory) review is a prime candidate for AI disruption precisely because its established, structured nature provides the necessary guardrails and historical data for AI to be effective.

Regulators like the FDA are actively encouraging the use of AI to improve clinical trial success rates. However, pharmaceutical companies are hesitant to adopt these innovative methods, fearing that any deviation from traditional processes will lead to costly delays or orders to restart the trial.

Healthcare is a model for AI governance beyond its regulatory framework. The industry has a pre-existing infrastructure of trust, experience with diverse use cases, established practices for post-deployment monitoring, and a deep understanding of human-in-the-loop systems, all directly applicable to AI.

AI adoption in drug companies isn't about moonshot discovery via a single prompt. Its immediate, high-impact use is in automating and error-proofing massive regulatory documents for the FDA, where a single misplaced comma can cause costly, multi-billion dollar delays.

The competitive advantage in pharma isn't the sophistication of an AI algorithm, which is often a commodity built on third-party models. The true differentiator is the quality, relevance, and end-to-end consistency of the proprietary data used to train and validate these models. Poor data invalidates even the best analytics.

Similar to how the rise of the internet forced every retail company to adopt e-commerce, the advancement of AI will mandate that every surviving pharmaceutical company becomes 'AI-native.' This isn't an optional upgrade but a fundamental business model shift necessary for survival in the coming years.